17 results on '"Timothy D. Mchugh"'
Search Results
2. End of the Bedaquiline patent – a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income countries
- Author
-
Eskild Petersen, David S. Hui, Jean B. Nachega, Francine Ntoumi, Delia Goletti, Eleni Aklillu, Avinash Sharma, Thomas Nyirenda, Dorothy Yeboah-Manu, Giovanni Satta, Christopher da Costa, Esam I. Azhar, Moses Bockarie, Seif Al-Abri, Timothy D. McHugh, Alfonso J. Rodriguez-Morales, George M Varghese, and Alimuddin Zumla
- Subjects
Infectious and parasitic diseases ,RC109-216 - Published
- 2023
- Full Text
- View/download PDF
3. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts
- Author
-
Eskild Petersen, Francine Ntoumi, David S Hui, Aisha Abubakar, Laura D. Kramer, Christina Obiero, Paul Anantharajah Tambyah, Lucille Blumberg, Richard Yapi, Seif Al-Abri, Tatiana de Castro Abreu Pinto, Dorothy Yeboah-Manu, Najmul Haider, Danny Asogun, Thirumalaisamy P. Velavan, Nathan Kapata, Matthew Bates, Rashid Ansumana, Chiara Montaldo, Luchenga Mucheleng'anga, John Tembo, Peter Mwaba, Cordelia M. Himwaze, Muzamil Mahdi Abdel Hamid, Sayoki Mfinanga, Leonard Mboera, Tajudeen Raj, Eleni Aklillu, Francisco Veas, Sarah Edwards, Pontiano Kaleebu, Timothy D. McHugh, Jeremiah Chakaya, Thomas Nyirenda, Moses Bockarie, Peter S Nyasulu, Christian Wejse, Jean-Jacques Muyembe-Tamfum, Esam I. Azhar, Markus Maeurer, Jean B. Nachega, Richard Kock, Giuseppe Ippolito, and Alimuddin Zumla
- Subjects
Infectious and parasitic diseases ,RC109-216 - Published
- 2022
- Full Text
- View/download PDF
4. Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future
- Author
-
Nathan Kapata, Chikwe Ihekweazu, Francine Ntoumi, Tajudeen Raji, Pascalina Chanda-Kapata, Peter Mwaba, Victor Mukonka, Matthew Bates, John Tembo, Victor Corman, Sayoki Mfinanga, Danny Asogun, Linzy Elton, Liã Bárbara Arruda, Margaret J. Thomason, Leonard Mboera, Alexei Yavlinsky, Najmul Haider, David Simons, Lara Hollmann, Swaib A. Lule, Francisco Veas, Muzamil Mahdi Abdel Hamid, Osman Dar, Sarah Edwards, Francesco Vairo, Timothy D. McHugh, Christian Drosten, Richard Kock, Giuseppe Ippolito, and Alimuddin Zumla
- Subjects
Infectious and parasitic diseases ,RC109-216 - Published
- 2020
- Full Text
- View/download PDF
5. Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts
- Author
-
Jeremiah Chakaya, Mishal Khan, Francine Ntoumi, Eleni Aklillu, Razia Fatima, Peter Mwaba, Nathan Kapata, Sayoki Mfinanga, Seyed Ehtesham Hasnain, Patrick D.M.C. Katoto, André N.H. Bulabula, Nadia A. Sam-Agudu, Jean B. Nachega, Simon Tiberi, Timothy D. McHugh, Ibrahim Abubakar, and Alimuddin Zumla
- Subjects
Tuberculosis ,Global TB Report 2020 ,Treatment ,Prevention ,Infectious and parasitic diseases ,RC109-216 - Abstract
The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in New York. Progress in TB care and prevention has been very slow. In 2019, TB remained the most common cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208, 000 deaths among people living with HIV. Adults accounted for 88% and children for 12% of people with TB. The WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%) had the most people with TB. Eight countries accounted for two thirds of the global total: India (26%), Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%) and South Africa (3.6%). Only 30% of the 3.5 million five-year target for children treated for TB was met. Major advances have been development of new all oral regimens for MDRTB and new regimens for preventive therapy. In 2020, the COVID-19 pandemic dislodged TB from the top infectious disease cause of mortality globally. Notably, global TB control efforts were not on track even before the advent of the COVID-19 pandemic. Many challenges remain to improve sub-optimal TB treatment and prevention services. Tuberculosis screening and diagnostic test services need to be ramped up. The major drivers of TB remain undernutrition, poverty, diabetes, tobacco smoking, and household air pollution and these need be addressed to achieve the WHO 2035 TB care and prevention targets. National programs need to include interventions for post-tuberculosis holistic wellbeing. From first detection of COVID-19 global coordination and political will with huge financial investments have led to the development of effective vaccines against SARS-CoV2 infection. The world now needs to similarly focus on development of new vaccines for TB utilizing new technological methods.
- Published
- 2021
- Full Text
- View/download PDF
6. Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak
- Author
-
Eskild Petersen, David Hui, Davidson H. Hamer, Lucille Blumberg, Lawrence C. Madoff, Marjorie Pollack, Shui Shan Lee, Susan McLellan, Ziad Memish, Ira Praharaj, Sean Wasserman, Francine Ntoumi, Esam Ibraheem Azhar, Timothy D. Mchugh, Richard Kock, Guiseppe Ippolito, Ali Zumla, and Marion Koopmans
- Subjects
Infectious and parasitic diseases ,RC109-216 - Published
- 2020
- Full Text
- View/download PDF
7. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China
- Author
-
David S. Hui, Esam I Azhar, Tariq A. Madani, Francine Ntoumi, Richard Kock, Osman Dar, Giuseppe Ippolito, Timothy D. Mchugh, Ziad A. Memish, Christian Drosten, Alimuddin Zumla, and Eskild Petersen
- Subjects
Infectious and parasitic diseases ,RC109-216 - Published
- 2020
- Full Text
- View/download PDF
8. Monkeypox — Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era
- Author
-
Eskild Petersen, Ibrahim Abubakar, Chikwe Ihekweazu, David Heymann, Francine Ntoumi, Lucille Blumberg, Danny Asogun, Victor Mukonka, Swaib Abubaker Lule, Matthew Bates, Isobella Honeyborne, Sayoki Mfinanga, Peter Mwaba, Osman Dar, Francesco Vairo, Maowia Mukhtar, Richard Kock, Timothy D. McHugh, Giuseppe Ippolito, and Alimuddin Zumla
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
The identification of monkeypox in 3 separate patients in the United Kingdom in September raised media and political attention on an emerging public health threat. Nigeria, whose last confirmed case of monkeypox was in 1978, is currently experiencing an unusually large and outbreak of human monkeypox cases, a ‘One Human-Environmental-Animal Health’ approach is being effectively used to define and tackle the outbreak. As of 13th October 2018, there have been one hundred and sixteen confirmed cases the majority of whom are under 40 years. Over the past 20 years ten Central and West African countries have reported monkeypox cases which have risen exponentially. We review the history and evolution of monkeypox outbreaks in Africa and USA, the changing clinical presentations, and discuss possible factors underlying the increasing numbers being detected including the cessation of smallpox vaccination programs. Major knowledge gaps remain on the epidemiology, host reservoir, and emergence, transmission, pathogenesis and prevention of monkeypoz.
- Published
- 2019
- Full Text
- View/download PDF
9. Who gets a laboratory positive diagnosis of Mycoplasma pneumoniae: A 10-year retrospective analysis
- Author
-
Charlotte Patterson, Marc Lipman, Damien Mack, and Timothy D. McHugh
- Subjects
Mycoplasma pneumoniae ,Serology ,Pneumonia ,Polymerase chain reaction ,Community acquired pneumonias ,Characteristics of the patients ,Infectious and parasitic diseases ,RC109-216 - Abstract
Objectives: Mycoplasma pneumoniae (M. pneumoniae) is thought to cause up to a third of community acquired pneumonias (CAP), but may be undiagnosed due to limitations with current diagnostics, and untreated given the frequent use of B-lactams to which M. pneumoniae is not susceptible. We performed a ten-year retrospective analysis to identify the typical characteristics of a patient with a laboratory positive diagnosis of M. pneumoniae. Methods: Laboratory diagnosis of M. pneumoniae was performed using Polymerase Chain Reaction (PCR) and Serology (passive particle agglutination (PPA) and Enzyme-linked immunosorbent (EIA) assays). Data were collected on all patients tested for M. pneumoniae between 2009 and 2019. Results: 19,090 PCR and 4530 serology samples were tested for M. pneumoniae with 278 positive results. The positive group had a median age of 40 years (interquartile range 30–41 years); Median C-reactive Protein (CRP) was 71 mg/L, White blood Cell Count (WBC) 7 × 109. 80% had an abnormal Chest X-ray. Intensive Care Unit (ICU) admission occurred in 4.5%; 1.3% patients died. 29% of patients were positive on both serology and PCR testing platforms. Conclusions: The characteristics reported here could be used as guidance on who is treated for M. pneumoniae. We propose that testing for M. pneumoniae needs to be performed systematically in patients with CAP; and that targeted atypical pathogen cover should be considered in preference to B-lactam mono-therapy for all patients with these characteristics.
- Published
- 2021
- Full Text
- View/download PDF
10. Enrichment of the airway microbiome in people living with HIV with potential pathogenic bacteria despite antiretroviral therapy
- Author
-
Sylvia A.D. Rofael, James Brown, Elisha Pickett, Margaret Johnson, John R. Hurst, David Spratt, Marc Lipman, and Timothy D. McHugh
- Subjects
Microbiota ,Bacteria/Classification ,16S rRNA sequencing ,HIV ,Infection ,Respiratory ,Medicine (General) ,R5-920 - Abstract
Background: Long-term antiretroviral therapy (ART) enables people living with HIV (PLW-HIV) to be healthier and live longer; though they remain at greater risk of pneumonia and chronic lung disease than the general population. Lung microbial dysbiosis has been shown to contribute to respiratory disease. Methods: 16S-rRNA gene sequencing on the Miseq-platform and qPCR for typical respiratory pathogens were performed on sputum samples collected from 64 PLW-HIV (median blood CD4 count 676 cells/μL) and 38 HIV-negative participants. Finding: Richness and α-diversity as well as the relative-abundance (RA) of the major taxa (RA>1%) were similar between both groups. In unweighted-Unifrac ß-diversity, the samples from PLW-HIV showed greater diversity, in contrast to the HIV negative samples which clustered together. Gut bacterial taxa such as Bilophila and members of Enterobacteriaceae as well as pathogenic respiratory taxa (Staphylococcus, Pseudomonas and Klebsiella) were significantly more frequent in PLW-HIV and almost absent in the HIV-negative group. Carriage of these taxa was correlated with the length of time between HIV diagnosis and initiation of ART (Spearman-rho=0·279, p=0·028). Interpretation: Although the core airway microbiome was indistinguishable between PLW-HIV on effective ART and HIV-negative participants, PLW-HIV's respiratory microbiome was enriched with potential respiratory pathogens and gut bacteria. The observed differences in PLW-HIV may be due to HIV infection altering the local lung microenvironment to be more permissive to harbour pathogenic bacteria that could contribute to respiratory comorbidities. Prompt start of ART for PLW-HIV may reduce this risk.
- Published
- 2020
- Full Text
- View/download PDF
11. Rapid identification of a Mycobacterium tuberculosis full genetic drug resistance profile through whole genome sequencing directly from sputum
- Author
-
Camus Nimmo, Ronan Doyle, Carrie Burgess, Rachel Williams, Rebecca Gorton, Timothy D. McHugh, Mike Brown, Stephen Morris-Jones, Helen Booth, and Judith Breuer
- Subjects
Tuberculosis ,Whole genome sequencing ,Drug resistance ,Clinical samples ,Directly from sputum ,Infectious and parasitic diseases ,RC109-216 - Abstract
Introduction: Resistance to second-line tuberculosis drugs is common, but slow to diagnose with phenotypic drug sensitivity testing. Rapid molecular tests speed up diagnosis, but can only detect limited mutations. Whole genome sequencing (WGS) of culture isolates can generate a complete genetic drug resistance profile, but is delayed by the initial culture step. In the case presented here, successful WGS directly from sputum was achieved using targeted enrichment. Case report: A 29-year-old Nigerian woman was diagnosed with tuberculosis. Xpert MTB/RIF and Hain line probe assays identified rpoB and inhA mutations consistent with rifampicin and intermediate isoniazid resistance, and a further possible mutation conferring fluoroquinolone resistance. WGS directly from sputum identified a further inhA mutation consistent with high-level isoniazid resistance and confirmed the absence of fluoroquinolone resistance. Isoniazid was stopped, and the patient has completed 18 months of a fluoroquinolone-based regimen without relapse. Discussion: Compared to rapid molecular tests (which can only examine a limited number of mutations) and WGS of culture isolates (which requires a culture step), WGS directly from sputum can quickly generate a complete genetic drug resistance profile. In this case, WGS altered the clinical management of drug-resistant tuberculosis and demonstrated potential for guiding individualized drug treatment where second-line drug resistance is common.
- Published
- 2017
- Full Text
- View/download PDF
12. Commemorating World Tuberculosis Day 2015
- Author
-
Alimuddin Zumla, Markus Maeurer, Ben Marais, Jeremiah Chakaya, Christian Wejse, Marc Lipman, Timothy D. McHugh, and Eskild Petersen
- Subjects
Infectious and parasitic diseases ,RC109-216 - Published
- 2015
- Full Text
- View/download PDF
13. Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts
- Author
-
Peter Mwaba, Razia Fatima, Sayoki Mfinanga, Alimuddin Zumla, André N.H. Bulabula, Simon Tiberi, Patrick D. M. C. Katoto, Timothy D. McHugh, Seyed E. Hasnain, Eleni Aklillu, Ibrahim Abubakar, Francine Ntoumi, Nathan Kapata, Mishal S Khan, Jeremiah Chakaya, Nadia A. Sam-Agudu, and Jean B. Nachega
- Subjects
Adult ,0301 basic medicine ,Microbiology (medical) ,Tuberculosis ,030106 microbiology ,Psychological intervention ,Nigeria ,wa_395 ,Infectious and parasitic diseases ,RC109-216 ,Disease ,Article ,wa_110 ,03 medical and health sciences ,0302 clinical medicine ,COVID-19 ,Prevention ,Treatment ,Global TB Report 2020 ,Environmental health ,Pandemic ,Humans ,Medicine ,030212 general & internal medicine ,wf_310 ,Child ,China ,Pandemics ,Poverty ,SARS-CoV-2 ,Tuberculosis, Miliary ,business.industry ,General Medicine ,medicine.disease ,Malnutrition ,Infectious Diseases ,Infectious disease (medical specialty) ,wf_140 ,RNA, Viral ,wf_200 ,business - Abstract
The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in New York. Progress in TB care and prevention has been very slow. In 2019, TB remained the most common cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208, 000 deaths among people living with HIV. Adults accounted for 88% and children for 12% of people with TB. The WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%) had the most people with TB. Eight countries accounted for two thirds of the global total: India (26%), Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%) and South Africa (3.6%). Only 30% of the 3.5 million five-year target for children treated for TB was met. Major advances have been development of new all oral regimens for MDRTB and new regimens for preventive therapy. In 2020, the COVID-19 pandemic dislodged TB from the top infectious disease cause of mortality globally. Notably, global TB control efforts were not on track even before the advent of the COVID-19 pandemic. Many challenges remain to improve sub-optimal TB treatment and prevention services. Tuberculosis screening and diagnostic test services need to be ramped up. The major drivers of TB remain undernutrition, poverty, diabetes, tobacco smoking, and household air pollution and these need be addressed to achieve the WHO 2035 TB care and prevention targets. National programs need to include interventions for post-tuberculosis holistic wellbeing. From first detection of COVID-19 global coordination and political will with huge financial investments have led to the development of effective vaccines against SARS-CoV2 infection. The world now needs to similarly focus on development of new vaccines for TB utilizing new technological methods.
- Published
- 2021
14. Enrichment of the airway microbiome in people living with HIV with potential pathogenic bacteria despite antiretroviral therapy
- Author
-
James Brown, Elisha Pickett, Margaret Johnson, John R. Hurst, Marc Lipman, Sylvia A.D. Rofael, Timothy D. McHugh, and David A. Spratt
- Subjects
Research paper ,Population ,Bacteria/Classification ,medicine.disease_cause ,01 natural sciences ,03 medical and health sciences ,0302 clinical medicine ,medicine ,030212 general & internal medicine ,Microbiome ,0101 mathematics ,Respiratory system ,education ,education.field_of_study ,lcsh:R5-920 ,Lung ,business.industry ,Microbiota ,010102 general mathematics ,Respiratory disease ,virus diseases ,HIV ,Pathogenic bacteria ,General Medicine ,medicine.disease ,16S rRNA sequencing ,Pneumonia ,medicine.anatomical_structure ,Immunology ,Respiratory ,Sputum ,medicine.symptom ,business ,lcsh:Medicine (General) ,Infection - Abstract
Background Long-term antiretroviral therapy (ART) enables people living with HIV (PLW-HIV) to be healthier and live longer; though they remain at greater risk of pneumonia and chronic lung disease than the general population. Lung microbial dysbiosis has been shown to contribute to respiratory disease. Methods 16S-rRNA gene sequencing on the Miseq-platform and qPCR for typical respiratory pathogens were performed on sputum samples collected from 64 PLW-HIV (median blood CD4 count 676 cells/μL) and 38 HIV-negative participants. Finding Richness and α-diversity as well as the relative-abundance (RA) of the major taxa (RA>1%) were similar between both groups. In unweighted-Unifrac s-diversity, the samples from PLW-HIV showed greater diversity, in contrast to the HIV negative samples which clustered together. Gut bacterial taxa such as Bilophila and members of Enterobacteriaceae as well as pathogenic respiratory taxa (Staphylococcus, Pseudomonas and Klebsiella) were significantly more frequent in PLW-HIV and almost absent in the HIV-negative group. Carriage of these taxa was correlated with the length of time between HIV diagnosis and initiation of ART (Spearman-rho=0·279, p=0·028). Interpretation Although the core airway microbiome was indistinguishable between PLW-HIV on effective ART and HIV-negative participants, PLW-HIV's respiratory microbiome was enriched with potential respiratory pathogens and gut bacteria. The observed differences in PLW-HIV may be due to HIV infection altering the local lung microenvironment to be more permissive to harbour pathogenic bacteria that could contribute to respiratory comorbidities. Prompt start of ART for PLW-HIV may reduce this risk.
- Published
- 2020
15. The complex evolution of antibiotic resistance in Mycobacterium tuberculosis
- Author
-
Timothy D. McHugh, Gwenan M. Knight, and J.D. Fonseca
- Subjects
Microbiology (medical) ,Tuberculosis ,medicine.drug_class ,Extensively Drug-Resistant Tuberculosis ,Antibiotics ,Drug resistance ,Disease ,Biology ,lcsh:Infectious and parasitic diseases ,Mycobacterium tuberculosis ,03 medical and health sciences ,Antibiotic resistance ,Drug Resistance, Multiple, Bacterial ,Tuberculosis, Multidrug-Resistant ,medicine ,Humans ,Molecular mechanisms of resistance ,lcsh:RC109-216 ,030304 developmental biology ,0303 health sciences ,030306 microbiology ,Extensively drug-resistant tuberculosis ,General Medicine ,Biological evolution ,medicine.disease ,biology.organism_classification ,Virology ,Biological Evolution ,3. Good health ,Infectious Diseases - Abstract
SummaryMultidrug-resistant and extensively drug-resistant tuberculosis (TB) represent a major threat to the control of the disease worldwide. The mechanisms and pathways that result in the emergence and subsequent fixation of resistant strains of Mycobacterium tuberculosis are not fully understood and recent studies suggest that they are much more complex than initially thought. In this review, we highlight the exciting new areas of research within TB resistance that are beginning to fill these gaps in our understanding, whilst also raising new questions and providing future directions.
- Published
- 2015
16. Commemorating World Tuberculosis Day 2015
- Author
-
Jeremiah Chakaya, Ben J. Marais, Marc Lipman, Alimuddin Zumla, Timothy D. McHugh, Eskild Petersen, Markus Maeurer, and Christian Wejse
- Subjects
Microbiology (medical) ,Tuberculosis ,business.industry ,Tb control ,Political awareness ,General Medicine ,medicine.disease ,Resistant tuberculosis ,lcsh:Infectious and parasitic diseases ,Infectious Diseases ,Infectious disease (medical specialty) ,Global health ,Medicine ,lcsh:RC109-216 ,Robert koch ,Socioeconomics ,business - Abstract
World Tuberculosis (TB) Day falls on March 24th each year, the day in 1882 when Professor Robert Koch announced his discovery of the microbial aetiology of TB, Mycobacterium tuberculosis (M. tb). One hundred and thirty three years later, despite an effective cure available for the past half century, TB continues to plague humankind and remains one of the most common causes of death from an infectious disease worldwide. The latest WHO annual Global TB report estimates that in 2013, there were 9 million people who developed TB of which an estimated 1.2 million (14%) were people living with HIV. 1 An ominous increase is being seen globally in the number of new cases of Multi-Drug Resistant TB (MDR-TB) and Extensively DrugResistant TB (XDR-TB) with an estimated 480,000 new cases of MDR-TB globally in 2013. 2 World TB Day 2015 gives us an opportunity to reflect on the trials and tribulations of global TB control efforts, and to raise public and political awareness that TB today remains a ‘global emergency’, is responsible for 1.5 million deaths each year globally, and that MDR-TB and XDR-TB in Europe, Asia and southern Africa are now major threats to global health security. To commemorate World TB Day on March 24 th 2015, we
- Published
- 2015
17. Mycobacterium tuberculosis and whole-genome sequencing: how close are we to unleashing its full potential?
- Author
-
G.P. Smith, Timothy D. McHugh, Giovanni Satta, Onn Min Kon, Marc Lipman, and C. Arnold
- Subjects
0301 basic medicine ,Microbiology (medical) ,Tuberculosis ,030106 microbiology ,MEDLINE ,Computational biology ,Microbiology ,DNA sequencing ,Disease Outbreaks ,Mycobacterium tuberculosis ,03 medical and health sciences ,Drug Resistance, Bacterial ,medicine ,Humans ,Whole genome sequencing ,biology ,business.industry ,High-Throughput Nucleotide Sequencing ,1103 Clinical Sciences ,General Medicine ,Drug susceptibility ,biology.organism_classification ,medicine.disease ,Biotechnology ,Anti-Bacterial Agents ,Bacterial Typing Techniques ,Infectious Diseases ,Drug resistance ,Applications ,Narrative review ,business ,Genome, Bacterial - Abstract
BACKGROUND: Nearly two decades after completion of the genome sequence of Mycobacterium tuberculosis (MTB), and with the advent of next generation sequencing technologies (NGS), whole-genome sequencing (WGS) has been applied to a wide range of clinical scenarios. Starting in 2017, England is the first country in the world to pioneer its use on a national scale for the diagnosis of tuberculosis, detection of drug resistance, and typing of MTB. AIMS: This narrative review critically analyses the current applications of WGS for MTB and explains how close we are to realizing its full potential as a diagnostic, epidemiologic, and research tool. SOURCES: We searched for reports (both original articles and reviews) published in English up to 31 May 2017, with combinations of the following keywords: whole-genome sequencing, Mycobacterium, and tuberculosis. MEDLINE, Embase, and Scopus were used as search engines. We included articles that covered different aspects of whole-genome sequencing in relation to MTB. CONTENT: This review focuses on three main themes: the role of WGS for the prediction of drug susceptibility, MTB outbreak investigation and genetic diversity, and research applications of NGS. IMPLICATIONS: Many of the original expectations have been accomplished, and we believe that with its unprecedented sensitivity and power, WGS has the potential to address many unanswered questions in the near future. However, caution is still needed when interpreting WGS data as there are some important limitations to be aware of, from correct interpretation of drug susceptibilities to the bioinformatic support needed.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.